Sunday 01 August 2010


print
Session 5: Therapeutic Drug Monitoring

 

Regulatory issues related to fixed dose combination drugs for the treatment of HIV infection – FDA perspective

 

K. Schoolar Reynolds

 

POPIN- a pilot study of TDM and adherence support

 

S. Khoo

 

Atazanavir Ctrough is associated with efficacy and safety at 24 weeks: Definition of therapeutic range

 

S. Bonora

 

 

Predictability of individual Nelfinavir (NFV) concentrations at different time points for total systemic exposure in HIV and HIV/HCV co-infected patients, with and without cirrhosis

 

M. Regazzi

 



disclaimer